Emerging Opportunities in In Situ Hybridization
This article was originally published in Start Up
In-situ hybridization (ISH) is a powerful method of genetic testing. But it has not yet found a place in the clinical laboratory. In addition to technical, patent and regulatory obstacles, participants will confront a fragmented market composed currently of high-priced, low-volume tests. Many scientists believe ISH will have an important role in the clinical laboratory, while others see it mostly as an interim technology likely to be superseded by easier-to-use DNA chips.
You may also be interested in...
Vysis Preps For Prime Time
Tiny Vysis scored big this spring, winning the backing of two major therapeutic and diagnostic companies for its products. But is its core technology ready for prime time? Vysis sees an opportunity to expand use of its FISH diagnostics technology beyond niche applications in the clinical market. But skeptics say the technology is too complex and expensive for routine clinical use.
US FDA Complete Response Letter Rates Vary With Sponsor Size
Pink Sheet infographic illustrates benefits of big pharma’s resources and experience.
Is It Time To Promote US FDA’s Biosimilars Office Out Of OND?
Making the Office of Therapeutic Biologics and Biosimilars a stand-alone office in CDER may allow it to add more expertise, but is there an appetite for another reorganization?